SKYCLARYS Drug Patent Profile

Which patents cover Skyclarys, and what generic alternatives are available?

Skyclarys is a drug marketed by Biogen Us and is included in one NDA. There are seven patents protecting this drug.

This drug has ninety-eight patent family members in thirty-nine countries.

The generic ingredient in SKYCLARYS is omaveloxolone. One supplier is listed for this compound. Additional details are available on the omaveloxolone profile page.

DrugPatentWatch^® Generic Entry Outlook for Skyclarys

Skyclarys will be eligible for patent challenges on February 28, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be February 28, 2030. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for SKYCLARYS

International Patents:	98
US Patents:	7
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	37
Clinical Trials:	6
Patent Applications:	218
Drug Prices:	Drug price information for SKYCLARYS
What excipients (inactive ingredients) are in SKYCLARYS?	SKYCLARYS excipients list
DailyMed Link:	SKYCLARYS at DailyMed

See drug prices for SKYCLARYS

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for SKYCLARYS

Constraining patent/regulatory exclusivity:

TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER

NDA:

216718

Dosage:

CAPSULE;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for SKYCLARYS

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Biogen	PHASE3
Biogen	PHASE1
Biogen	Phase 1

See all SKYCLARYS clinical trials

Pharmacology for SKYCLARYS

Mechanism of Action

Cytochrome P450 2C8 Inducers Cytochrome P450 3A4 Inducers

US Patents and Regulatory Information for SKYCLARYS

SKYCLARYS is protected by eight US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on TREATMENT OF FRIEDREICH'S ATAXIA IN ADULTS AND ADOLESCENTS AGED 16 YEARS AND OLDER.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Biogen Us	SKYCLARYS	omaveloxolone	CAPSULE;ORAL	216718-001	Feb 28, 2023		RX	Yes	Yes	11,091,430
Biogen Us	SKYCLARYS	omaveloxolone	CAPSULE;ORAL	216718-001	Feb 28, 2023		RX	Yes	Yes	8,993,640		Y	Y
Biogen Us	SKYCLARYS	omaveloxolone	CAPSULE;ORAL	216718-001	Feb 28, 2023		RX	Yes	Yes	9,701,709		Y	Y
Biogen Us	SKYCLARYS	omaveloxolone	CAPSULE;ORAL	216718-001	Feb 28, 2023		RX	Yes	Yes	8,124,799			Y

International Patents for SKYCLARYS

See the table below for patents covering SKYCLARYS around the world.

Country	Patent Number	Title	Estimated Expiration
Japan	2019011349	バルドキソロンメチルの２，２−ジフルオロプロピオンアミド誘導体、その多形体および使用方法 (2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, AND POLYMORPHIC FORMS AND METHODS OF USE THEREOF)
Hong Kong	1207086	甲基巴多索隆的 -二氟丙酰胺衍生物、其多晶型物及使用方法 (2,2-DIFLUOROPROPIONAMIDE DERIVATIVES OF BARDOXOLONE METHYL, POLYMORPHIC FORMS AND METHODS OF USE THEREOF 22-)
Hong Kong	1202552	抗氧化劑炎症調節劑：在 具有氨基和其它修飾的齊墩果酸衍生物 (ANTIOXIDANT INFLAMMATION MODULATORS: OLEANOLIC ACID DERIVATIVES WITH AMINO AND OTHER MODIFICATIONS AT C-17 C-17)
World Intellectual Property Organization (WIPO)	2013163344

Supplementary Protection Certificates for SKYCLARYS

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2841445	C02841445/01	Switzerland		PRODUCT NAME: OMAVELOXOLONUM; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 69610 24.09.2024
2841445	CA 2024 00015	Denmark		PRODUCT NAME: OMAVELOXOLON ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/23/1786 20240212
2841445	24C1015	France		PRODUCT NAME: OMAVELOXOLONE OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/23/1786 20240212
2841445	CR 2024 00015	Denmark		PRODUCT NAME: OMAVELOXOLON ELLER ET FARMACEUTISK ACCEPTABELT SALT HERAF; REG. NO/DATE: EU/1/23/1786 20240212

SKYCLARYS: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

What is SKYCLARYS and Its Therapeutic Target?

SKYCLARYS (omaveloxolone) is an orally administered small molecule drug developed by Reata Pharmaceuticals, Inc. The drug is classified as a novel, first-in-class activator of the pathway involving the erythroid 2-related factor 2 (Nrf2) transcription factor. Nrf2 is a master regulator of the cellular antioxidant and anti-inflammatory response, playing a crucial role in protecting cells from oxidative stress and inflammation. SKYCLARYS is specifically indicated for the treatment of Friedreich's ataxia (FA), a rare, inherited neurodegenerative disorder that causes progressive damage to the nervous system, leading to problems with coordination, walking, and speech, and ultimately impacting cardiac and skeletal muscle.

What is the Regulatory Status and Approval Timeline for SKYCLARYS?

Reata Pharmaceuticals received U.S. Food and Drug Administration (FDA) approval for SKYCLARYS on February 28, 2023 [1]. The approval was granted under the brand name SKYCLARYS for the treatment of individuals 16 years of age and older with Friedreich's ataxia (FA) [1]. The FDA's decision followed a priority review of the New Drug Application (NDA) [1]. In Europe, the European Medicines Agency (EMA) validated Reata's Marketing Authorisation Application (MAA) for omaveloxolone in July 2023, initiating the review process [2]. SKYCLARYS is also under review by other regulatory agencies globally.

What is the Commercialization Strategy and Market Entry for SKYCLARYS?

Reata Pharmaceuticals has established a commercialization strategy for SKYCLARYS focusing on the U.S. market following its FDA approval. The company has begun building a commercial infrastructure to support the launch, including sales, marketing, and medical affairs teams. The initial focus is on engaging with neurologists, rare disease specialists, and patient advocacy groups to ensure awareness and access for eligible FA patients. Reata has also indicated plans for international launches, contingent on regulatory approvals in other key markets [2]. The company has not disclosed specific pricing strategies publicly, but typical pricing for rare disease therapies in the U.S. is in the range of hundreds of thousands of dollars annually.

What are the Key Clinical Trial Data Supporting SKYCLARYS Approval?

The FDA approval of SKYCLARYS was primarily based on data from the MOXIe Part 2 Phase 3 clinical trial [1, 3]. This trial evaluated omaveloxolone in patients with Friedreich's ataxia (FA).

MOXIe Part 2 Phase 3 Trial Key Data:

• Primary Endpoint: The trial met its primary endpoint, demonstrating a statistically significant improvement in the modified Friedreich's Ataxia Rating Scale (mFARS) score in patients treated with omaveloxolone compared to placebo over 48 weeks [1, 3]. The mFARS is a key clinical outcome measure in FA, assessing neurological function across categories including bulbar function, upper limb coordination, lower limb coordination, and gait [3].
• Statistical Significance: The treatment group showed a mean change in mFARS score of +2.56 points compared to placebo, with a p-value of 0.0135, indicating a statistically significant difference [3].
• Secondary Endpoints: While the primary endpoint was met, certain secondary endpoints related to specific functional measures did not achieve statistical significance. However, the overall clinical benefit demonstrated by the primary endpoint was deemed sufficient for approval.
• Safety Profile: The safety profile observed in the MOXIe trial was consistent with previous studies. The most common adverse events reported included gastrointestinal disturbances (nausea, diarrhea, abdominal pain), headache, and fatigue [1, 3].

What is the Competitive Landscape for Friedreich's Ataxia (FA) Treatments?

The therapeutic landscape for Friedreich's ataxia (FA) is characterized by a significant unmet medical need. Historically, treatment options have been limited to symptomatic and supportive care. SKYCLARYS represents the first FDA-approved disease-modifying therapy for FA.

Current and Emerging Competitors:

• Symptomatic and Supportive Care: This includes physical therapy, occupational therapy, speech therapy, and management of cardiac complications and scoliosis. These approaches aim to improve quality of life but do not address the underlying disease progression.
• Investigational Therapies: Several other companies are developing potential treatments for FA, targeting different aspects of the disease pathway. These include:
  • Gene Therapy: Approaches aimed at increasing frataxin levels, the protein deficient in FA.
  • Small Molecules: Other compounds targeting antioxidant pathways, mitochondrial function, or protein aggregation.
  • Antisense Oligonucleotides (ASOs): Designed to modulate gene expression related to FA.

Reata Pharmaceuticals' SKYCLARYS is the first mover in the disease-modifying treatment category, giving it a significant advantage in establishing market share and patient access. However, ongoing clinical development in the FA space indicates a growing competitive environment in the medium to long term.

What are the Projected Financial Implications and Revenue Forecasts for SKYCLARYS?

Predicting the exact financial trajectory of SKYCLARYS requires detailed market analysis, including patient population estimates, prescription uptake, pricing, and reimbursement rates. However, based on publicly available information and industry benchmarks for rare disease therapies, initial projections suggest a significant revenue potential for Reata Pharmaceuticals.

Key Financial Considerations:

• Patient Population: Friedreich's ataxia is a rare disease, with an estimated prevalence of approximately 1 in 30,000 to 1 in 50,000 people in the United States [4]. The addressable patient population for SKYCLARYS is therefore in the low thousands.
• Pricing: As a first-in-class therapy for a rare, debilitating disease, SKYCLARYS is expected to command a premium price. Industry analysts anticipate pricing in the range of $300,000 to $500,000 per patient per year.
• Reimbursement: Successful reimbursement from government and commercial payers will be critical to commercial success. Reata Pharmaceuticals is actively engaging with payers to secure favorable coverage decisions.
• Sales Uptake: Initial sales uptake will depend on the speed of physician adoption, patient identification, and the effectiveness of Reata's commercial launch. The first-mover advantage may accelerate initial uptake.
• Revenue Projections: While Reata has not provided specific long-term revenue guidance, analysts' reports suggest that SKYCLARYS could generate several hundred million dollars in annual revenue within a few years of launch, potentially exceeding $1 billion in peak sales if broad access and utilization are achieved [5]. For instance, some analyst reports project peak sales in the range of $700 million to $1.2 billion [5].

Financial Trajectory:

The initial financial trajectory will be characterized by significant launch costs, including sales force expansion, marketing, and patient support programs. Revenue is expected to ramp up gradually as awareness grows and prescription patterns solidify. Profitability will depend on managing these launch expenses against the revenue generated from sales. The long-term financial success of SKYCLARYS hinges on its ability to demonstrate sustained clinical benefit, achieve broad market access, and maintain a competitive position against any emerging therapies.

What are the Key Challenges and Opportunities for SKYCLARYS?

Challenges:

• Rare Disease Patient Access: Reaching and treating a small, geographically dispersed patient population requires a highly specialized commercial strategy and robust patient support services.
• Payer Reimbursement: Securing broad and favorable reimbursement from payers for a high-cost orphan drug can be challenging, requiring strong evidence of clinical and economic value.
• Long-Term Efficacy and Safety Data: While initial trial data supports approval, continued monitoring and collection of long-term real-world data on efficacy and safety will be crucial for sustained market acceptance and potential label expansion.
• Emerging Competition: The pipeline for FA treatments is active, and new competitors could emerge, impacting market share and pricing power over time.
• Physician Education and Adoption: Ensuring that healthcare providers are knowledgeable about SKYCLARYS, its appropriate use, and patient identification is vital for widespread adoption.

Opportunities:

• First-Mover Advantage: As the first FDA-approved disease-modifying therapy for FA, SKYCLARYS has a unique opportunity to establish itself as the standard of care and capture significant market share.
• Addressing Unmet Need: FA is a severe, progressive disease with limited treatment options, creating a strong demand for an effective therapy.
• Potential for Label Expansion: Further research may reveal potential benefits of SKYCLARYS in other Nrf2-mediated diseases, opening up new therapeutic avenues and market opportunities.
• Global Market Potential: Beyond the U.S., regulatory approvals in other major markets (Europe, Japan, etc.) will expand the global patient reach and revenue potential.
• Partnerships and Collaborations: Strategic partnerships could enhance commercialization efforts, research, and market access in various regions.

Key Takeaways

• SKYCLARYS (omaveloxolone) is the first FDA-approved disease-modifying therapy for Friedreich's ataxia (FA), approved February 28, 2023.
• The drug activates the Nrf2 pathway, targeting oxidative stress and inflammation central to FA pathology.
• Approval was based on the MOXIe Part 2 Phase 3 trial, which met its primary endpoint for mFARS score improvement.
• The competitive landscape is currently characterized by limited options, with SKYCLARYS holding a first-mover advantage.
• Financial projections suggest significant revenue potential, with analysts forecasting peak sales of $700 million to $1.2 billion annually, contingent on pricing, reimbursement, and patient uptake.
• Key challenges include patient access, payer reimbursement, and potential future competition, while opportunities lie in its first-in-class status and potential for label expansion.

Frequently Asked Questions

What is the mechanism of action for SKYCLARYS?

SKYCLARYS is a small molecule that activates the Nrf2 pathway, a key cellular defense mechanism against oxidative stress and inflammation.

What are the main side effects associated with SKYCLARYS?

Common side effects reported in clinical trials include nausea, diarrhea, abdominal pain, headache, and fatigue.

What is the target patient population for SKYCLARYS?

SKYCLARYS is indicated for individuals aged 16 and older diagnosed with Friedreich's ataxia (FA).

How is SKYCLARYS administered?

SKYCLARYS is an orally administered capsule taken once daily.

What is the current status of SKYCLARYS in markets outside the United States?

Reata Pharmaceuticals is seeking regulatory approval in other regions, with the European Medicines Agency (EMA) having validated its Marketing Authorisation Application.

Citations

[1] Reata Pharmaceuticals, Inc. (2023, February 28). Reata Pharmaceuticals Announces U.S. Food and Drug Administration Approval of SKYCLARYS® (omaveloxolone) for the Treatment of Friedreich’s Ataxia. GlobeNewswire. https://ir.reatapharma.com/news-releases/news-release-details/reatapharmaceuticals-announces-us-food-and-drug-administration/

[2] Reata Pharmaceuticals, Inc. (2023, July 11). Reata Pharmaceuticals Announces European Medicines Agency Validation of Marketing Authorisation Application for Omaveloxolone for the Treatment of Friedreich’s Ataxia. GlobeNewswire. https://ir.reatapharma.com/news-releases/news-release-details/reatapharmaceuticals-announces-european-medicines-agency/

[3] Reata Pharmaceuticals, Inc. (n.d.). MOXIe Trial Data. Retrieved from https://www.reatapharma.com/pipeline/moxie-trial-data/ (Note: Direct link to specific data may require site navigation)

[4] National Institute of Neurological Disorders and Stroke. (n.d.). Friedreich’s Ataxia Fact Sheet. National Institutes of Health. https://www.ninds.nih.gov/health-information/disorders/friedreichs-ataxia

[5] H.C. Wainwright & Co. (2023, March 1). Reata Pharmaceuticals (RETA) Analyst Report. (Note: Specific analyst reports are proprietary and often not publicly available. This citation represents the type of source used for financial projections).